ZX6.F DSM-Firmenich AG
- Market cap
- EUR 25.9B
- P/E
- -
- P/B
- 1.44x
- ROE
- -5.9%
- Dividend yield
- 2.77%
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is ZX6.F undervalued?
Graham numberThe Graham number of DSM-Firmenich AG cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
DSM-Firmenich AG fundamental analysis
No fundamental analysis for DSM-Firmenich AG yet.
DSM-Firmenich AG stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About DSM-Firmenich AG
DSM-Firmenich AG provides nutrition, health, and beauty solutions in Switzerland, the Netherlands, rest of Europe, the Middle East and Africa, North America, Latin America, China, and rest of Asia. The company operates through Perfumery & Beauty; Taste, Texture & Health; and Health, Nutrition & Care segments. The Perfumery & Beauty creates scents using natural, synthetic, and biotech ingredients. The Taste, Texture & Health segment provides food and beverages solutions, incl…
Full company profileDSM-Firmenich AG financial statements
DSM-Firmenich AG annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 11.4B | 8.39B | 10.6B | 9.05B | 9.03B |
| Gross Profit | 4.19B | 2.69B | 2.61B | 3.55B | 3.53B |
| Operating Income | 816M | 657M | -507M | 551M | 632M |
| EBITDA | - | 1.38B | 501M | 1.77B | 3.85B |
| Net Income | 872M | 1.70B | 2.14B | 250M | -1.08B |
| EPS | - | 11 | 8.06 | 0.94 | -4.30 |
| Balance Sheet | |||||
| Total Assets | - | 17.4B | 34.3B | 33.7B | 29.3B |
| Total Liabilities | - | 6.56B | 11.2B | 11.1B | 10.9B |
| Shareholders' Equity | - | 10.7B | 22.9B | 22.5B | 18.2B |
| Cash & Short-term Investments | - | 2.76B | 2.46B | 2.67B | 1.78B |
| Cash Flow | |||||
| Operating Cash Flow | - | 965M | 1.27B | 1.78B | 1.45B |
| Capital Expenditure | 0.00 | 684M | 707M | 772M | 794M |
| Free Cash Flow | - | 281M | 558M | 1.01B | 651M |
| Ratios | |||||
| ROE | - | 15.8% | 9.3% | 1.1% | -5.9% |
| ROA | - | 9.8% | 6.2% | 0.7% | -3.7% |
| Net Profit Margin | 7.6% | 20.3% | 20.1% | 2.8% | -12.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
DSM-Firmenich AG dividends
- Dividend yield
- 2.77%
- Forward dividend
- 2.50 EUR
- Payout ratio
- -
- Ex-dividend date
- May 11, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | EUR 718M | 2.85 | - |
| 2024 | EUR 667M | 2.51 | 266.8% |
| 2023 | EUR 582M | 2.19 | 27.2% |
| 2022 | EUR 345M | 2.29 | 20.3% |
| 2021 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns DSM-Firmenich AG
- Insiders 9.49%
- Institutions 53.95%
- Public & others 36.57%
- Shares outstanding 244M
- Free float 225M
DSM-Firmenich AG company profile
- Company name
- DSM-Firmenich AG
- Ticker
- ZX6.F
- ISIN
- CH1216478797
- Exchange
- Frankfurt Exchange
- Sector
- Basic Materials
- Industry
- Specialty Chemicals
- Employees
- 20,786
- Fiscal year end
- December
- Address
- Wurmisweg 576, Kaiseraugst, Switzerland, 4303
- Phone
- 41 61 815 8888
- Website
- dsm-firmenich.com
About DSM-Firmenich AG
DSM-Firmenich AG provides nutrition, health, and beauty solutions in Switzerland, the Netherlands, rest of Europe, the Middle East and Africa, North America, Latin America, China, and rest of Asia. The company operates through Perfumery & Beauty; Taste, Texture & Health; and Health, Nutrition & Care segments. The Perfumery & Beauty creates scents using natural, synthetic, and biotech ingredients. The Taste, Texture & Health segment provides food and beverages solutions, including flavors, natural extracts, and sugar reduction; and food enzymes, hydrocolloids, cultures, natural colorants, nutritional ingredients, and plant-based proteins. The Health, Nutrition & Care segment provides solutions for the early life nutrition, dietary supplement, pharmaceutical, medical nutrition, biomedical materials, and nutrition improvement markets. This segment also offers vitamins, nutritional lipids, minerals, carotenoids, botanical nutraceuticals, digestive enzymes, postbiotics, probiotics and prebiotics, and active pharmaceutical ingredients; biomedical solutions; and premix, market-ready, and personalized nutrition solutions, as well as expert services in regulatory affairs and nutrition. DSM-Firmenich AG was founded in 1902 and is based in Kaiseraugst, Switzerland.
DSM-Firmenich AG management
10- Mr. Dimitri de VreezeChief Executive Officer · born 1967
- Mr. Ralf SchmeitzChief Financial Officer · born 1972
- Mr. Emmanuel ButstraenBU President of Perfumery & Beauty and COO · born 1968
- Dr. Sarah ReisingerChief Science & Research Officer · born 1979
- Mr. Dave HuizingSenior Vice President of Investor Relations
- Ms. Laetitia PictetChief Legal, Risk & Compliance Officer · born 1970
- Ms. Nikeisha van SleeuwenChief Human Resources Officer
- Mr. Philip EykermanChief Strategy, M&A and Transformation Officer · born 1969
- Ms. Jane SinclairAdvisor to the CEO · born 1962
- Ms. Katharina StenholmChief Sustainability Officer · born 1967